miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review)

Arora,Taruna; Kausar,Mohd. Adnan; Aboelnaga,Shimaa Mohammed; Anwar,Sadaf; Hussain,Malik Asif; Sadaf,Sadaf; Kaur,Simran; Eisa,Alaa Abdulaziz; Shingatgeri,Vyas Murti Madhavrao; Najm,Mohammad Zeeshan; Aloliqi,Abdulaziz A.

doi:10.3892/or.2022.8346

miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review)

Authors:
- Taruna Arora
- Mohd. Adnan Kausar
- Shimaa Mohammed Aboelnaga
- Sadaf Anwar
- Malik Asif Hussain
- Sadaf Sadaf
- Simran Kaur
- Alaa Abdulaziz Eisa
- Vyas Murti Madhavrao Shingatgeri
- Mohammad Zeeshan Najm
- Abdulaziz A. Aloliqi
View Affiliations

Affiliations: Division of Reproductive Biology, Maternal & Child Health, Department of Health Research, ICMR, MOHFW, Government of India, Ansari Nagar, New Delhi 110029, India, Department of Biochemistry, College of Medicine, University of Hail, Hail, KSA‑2240, Saudi Arabia, Deanship of Preparatory Year, University of Hail, Hail, KSA‑2240, Saudi Arabia, Department of Pathology, University of Hail, Hail, KSA-2240, Saudi Arabia, Department of Biotechnology, Jamia Millia Islamia, New Delhi 110025, India, School of Biosciences, Apeejay Stya University, Sohna, Haryana 122103, India, Department of Medical Laboratories Technology, College of Applied Medical Sciences, Taibah University, Medina, KSA‑344, Saudi Arabia, Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51542, Saudi Arabia
Published online on: June 10, 2022 https://doi.org/10.3892/or.2022.8346
Article Number: 135

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is recognized as the leading cause of death worldwide. The hippo signaling pathway regulates organ size by balancing cell proliferation and cell death; hence dysregulation of the hippo pathway promotes cancer‑like conditions. miRNAs are a type of non‑coding RNA that have been shown to regulate gene expression. miRNA levels are altered in various classes of cancer. Researchers have also uncovered a crosslinking between miRNAs and the hippo pathway, which has been linked to cancer. The components of the hippo pathway regulate miRNA synthesis, and various miRNAs regulate the components of the hippo pathway both positively and negatively, which can lead to cancer‑like conditions. In the present review article, the mechanism behind the hippo signaling pathway and miRNAs biogenesis and crosslinks between miRNAs and the hippo pathway, which result in cancer, shall be discussed. Furthermore, the article will cover miRNA‑related therapeutics and provide an overview of the development of resistance to anticancer drugs. Understanding the underlying processes would improve the chances of developing effective cancer treatment therapies.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of print). View Article : Google Scholar
2	Zygulska AL, Krzemieniecki K and Pierzchalski P: Hippo pathway-brief overview of its relevance in cancer. J Physiol Pharmacol. 68:311–335. 2017.PubMed/NCBI
3	Zeng R and Dong J: The Hippo signaling pathway in drug resistance in cancer. Cancers (Basel). 13:3182021. View Article : Google Scholar : PubMed/NCBI
4	Li N, Xie C and Lu N: Crosstalk between Hippo signaling and miRNAs in tumor progression. FEBS J. 284:1045–1055. 2017. View Article : Google Scholar : PubMed/NCBI
5	Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD and Gregory RI: Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 156:893–906. 2014. View Article : Google Scholar : PubMed/NCBI
6	Pfleger CM: The Hippo pathway: A master regulatory network important in development and dysregulated in disease. Curr Top Dev Biol. 123:181–228. 2017. View Article : Google Scholar : PubMed/NCBI
7	Dey A, Varelas X and Guan KL: Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 19:480–494. 2020. View Article : Google Scholar : PubMed/NCBI
8	Kaur S, Najm MZ, Khan MA, Akhter N, Shingatgeri VM, Sikenis M, Sadaf and Aloliqi AA: Drug-resistant breast cancer: Dwelling the Hippo pathway to manage the treatment. Breast Cancer (Dove Med Press). 13:691–700. 2021.PubMed/NCBI
9	Praskova M, Xia F and Avruch J: MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol. 18:311–321. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zheng Y and Pan D: The Hippo signaling pathway in development and disease. Dev Cell. 50:264–282. 2019. View Article : Google Scholar : PubMed/NCBI
11	Nguyen-Lefebvre AT, Selzner N, Wrana JL and Bhat M: The hippo pathway: A master regulator of liver metabolism, regeneration, and disease. FASEB J. 35:e215702021. View Article : Google Scholar : PubMed/NCBI
12	Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008. View Article : Google Scholar : PubMed/NCBI
14	Najm MZ, Sadaf, Shingatgeri VM, Saha H, Bhattacharya H, Rath A, Verma V, Gupta A, Aloliqi AA, Kashyap P and Parveen F: Hippo pathway in cancer: Examining its potential. J Curr Oncol. 4:115–120. 2021. View Article : Google Scholar
15	Badouel C and McNeill H: SnapShot: The hippo signaling pathway. Cell. 145:484.e12011.PubMed/NCBI
16	Huang YT, Lan Q, Lorusso G, Duffey N and Rüegg C: The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. Oncotarget. 8:9200–9215. 2017. View Article : Google Scholar : PubMed/NCBI
17	Niu J, Ma J, Guan X, Zhao X, Li P and Zhang M: Correlation between Doppler ultrasound blood flow parameters and angiogenesis and proliferation activity in breast cancer. Med Sci Monit. 25:70352019. View Article : Google Scholar : PubMed/NCBI
18	Yu FX and Guan KL: The Hippo pathway: Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
19	Han Y: Analysis of the role of the Hippo pathway in cancer. J Transl Med. 17:1162019. View Article : Google Scholar : PubMed/NCBI
20	Mo JS: The role of extracellular biophysical cues in modulating the Hippo-YAP pathway. BMB Rep. 50:71–78. 2017. View Article : Google Scholar : PubMed/NCBI
21	Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL: TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008. View Article : Google Scholar : PubMed/NCBI
22	Beyer TA, Weiss A, Khomchuk Y, Huang K, Ogunjimi AA, Varelas X and Wrana JL: Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 5:1611–1624. 2013. View Article : Google Scholar : PubMed/NCBI
23	Liu J, Kang R and Tang D: The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther. 2021 Sep 1;(Epub ahead of print). View Article : Google Scholar
24	Shen Z and Stanger BZ: YAP regulates S-phase entry in endothelial cells. PLoS One. 10:e01175222015. View Article : Google Scholar : PubMed/NCBI
25	Benham-Pyle BW, Pruitt BL and Nelson WJ: Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry. Science. 348:1024–1027. 2015. View Article : Google Scholar : PubMed/NCBI
26	Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 158:185–197. 2014. View Article : Google Scholar : PubMed/NCBI
27	Shibata M, Ham K and Hoque MO: A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 143:2133–2144. 2018. View Article : Google Scholar : PubMed/NCBI
28	Mytsyk Y, Dosenko V, Skrzypczyk MA, Borys Y, Diychuk Y, Kucher A, Kowalskyy V, Pasichnyk S, Mytsyk O and Manyuk L: Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma. Cent European J Urol. 71:295–303. 2018.PubMed/NCBI
29	O'Brien J, Hayder H, Zayed Y and Peng C: Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 9:4022018. View Article : Google Scholar : PubMed/NCBI
30	Bushati N and Cohen SM: MicroRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
31	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
32	Wightman B, Ha I and Ruvkun G: Post-transcriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI
33	Hong Y, Lee RC and Ambros V: Structure and function analysis of LIN-14, a temporal regulator of postembryonic developmental events in Caenorhabditis elegans. Mol Cell Biol. 20:2285–2295. 2000. View Article : Google Scholar : PubMed/NCBI
34	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
35	Lau NC, Lim LP, Weinstein EG and Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
36	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
37	Croce CM and Calin GA: MiRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
38	Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is regulated by the microRNA pathway. Nature. 435:974–978. 2005. View Article : Google Scholar : PubMed/NCBI
39	Borchert GM, Lanier W and Davidson BL: RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 13:1097–1101. 2006. View Article : Google Scholar : PubMed/NCBI
40	Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH and Kim VN: MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23:4051–4060. 2004. View Article : Google Scholar : PubMed/NCBI
41	MacFarlane LA and R Murphy P: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
42	Pong SK and Gullerova M: Noncanonical functions of microRNA pathway enzymes-Drosha, DGCR 8, Dicer and Ago proteins. FEBS Lett. 592:2973–2986. 2018. View Article : Google Scholar : PubMed/NCBI
43	Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN: The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:3016–3027. 2004. View Article : Google Scholar : PubMed/NCBI
44	Wong CM, Tsang FH and Ng IO: Non-coding RNAs in hepatocellular carcinoma: Molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 15:137–151. 2018. View Article : Google Scholar : PubMed/NCBI
45	Valinezhad Orang A, Safaralizadeh R and Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics. 2014:9706072014. View Article : Google Scholar : PubMed/NCBI
46	Zhang HN, Xu QQ, Thakur A, Alfred MO, Chakraborty M, Ghosh A and Yu XB: Endothelial dysfunction in diabetes and hypertension: Role of microRNAs and long non-coding RNAs. Life Sci. 213:258–268. 2018. View Article : Google Scholar : PubMed/NCBI
47	Romano G and Kwong LN: MiRNAs, melanoma and microenvironment: An intricate network. Int J Mol Sci. 18:23542017. View Article : Google Scholar : PubMed/NCBI
48	Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshida I, Yoshimura K, Mihara M, Naitou M, Endoh H, Nakamura T, et al: DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol. 9:604–611. 2007. View Article : Google Scholar : PubMed/NCBI
49	Davis BN, Hilyard AC, Lagna G and Hata A: SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 454:56–61. 2008. View Article : Google Scholar : PubMed/NCBI
50	Alarcón CR, Lee H, Goodarzi H, Halberg N and Tavazoie SF: N6-methyladenosine marks primary microRNAs for processing. Nature. 519:482–485. 2015. View Article : Google Scholar : PubMed/NCBI
51	Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, Gherzi R and Rosenfeld MG: The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature. 459:1010–1014. 2009. View Article : Google Scholar : PubMed/NCBI
52	Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, et al: MiR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. 74:4145–4156. 2014. View Article : Google Scholar : PubMed/NCBI
53	Li L, Li C, Wang S, Wang Z, Jiang J, Wang W, Li X, Chen J, Liu K, Li C and Zhu G: Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res. 76:1770–1780. 2016. View Article : Google Scholar : PubMed/NCBI
54	Liu C, Kelnar K, Vlassov AV, Brown D, Wang J and Tang DG: Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 72:3393–3404. 2012. View Article : Google Scholar : PubMed/NCBI
55	Fu V, Plouffe SW and Guan KL: The Hippo pathway in organ development, homeostasis, and regeneration. Curr Opin Cell Biol. 49:99–107. 2017. View Article : Google Scholar : PubMed/NCBI
56	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
57	Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR and Camargo FD: Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell. 144:782–795. 2011. View Article : Google Scholar : PubMed/NCBI
58	Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N and Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. Nature. 432:235–240. 2004. View Article : Google Scholar : PubMed/NCBI
59	Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
60	Yu T, Ma P, Wu D, Shu Y and Gao W: Functions and mechanisms of microRNA-31 in human cancers. Biomed Pharmacother. 108:1162–1169. 2018. View Article : Google Scholar : PubMed/NCBI
61	Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al: MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 120:1298–1309. 2010. View Article : Google Scholar : PubMed/NCBI
62	Wu Y, Li M, Lin J and Hu C: Hippo/TEAD4 signaling pathway as a potential target for the treatment of breast cancer. Oncol Lett. 21:3132021. View Article : Google Scholar : PubMed/NCBI
63	Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K: The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
64	Duan J, Zhang H, Qu Y, Deng T, Huang D, Liu R, Zhang L, Bai M, Zhou L, Ying G and Ba Y: Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget. 7:44522–44533. 2016. View Article : Google Scholar : PubMed/NCBI
65	Zhang Y, Shen H, Withers HG, Yang N, Denson KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C and Zhang J: VGLL4 selectively represses YAP-dependent gene induction and tumorigenic phenotypes in breast cancer. Sci Rep. 7:61902017. View Article : Google Scholar : PubMed/NCBI
66	Cheng L, Wang H and Han S: MiR-3910 promotes the growth and migration of cancer cells in the progression of hepatocellular carcinoma. Dig Dis Sci. 62:2812–2820. 2017. View Article : Google Scholar : PubMed/NCBI
67	Liu AM, Poon RT and Luk JM: MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010. View Article : Google Scholar : PubMed/NCBI
68	Ruan T, He X, Yu J and Hang Z: MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma. Oncol Lett. 11:2941–2945. 2016. View Article : Google Scholar : PubMed/NCBI
69	Deng J, Lei W, Xiang X, Zhang L, Lei J, Gong Y, Song M, Wang Y, Fang Z, Yu F, et al: Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway. Oncotarget. 7:10037–10050. 2016. View Article : Google Scholar : PubMed/NCBI
70	Higashi T, Hayashi H, Ishimoto T, Takeyama H, Kaida T, Arima K, Taki K, Sakamoto K, Kuroki H, Okabe H, et al: MiR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Br J Cancer. 113:252–258. 2015. View Article : Google Scholar : PubMed/NCBI
71	Tan G, Cao X, Dai Q, Zhang B, Huang J, Xiong S, Zhang Yy, Chen W, Yang J and Li H: A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
72	Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, Nan KJ and Han LL: MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 8:99757–99771. 2017. View Article : Google Scholar : PubMed/NCBI
73	Abd-Aziz N, Kamaruzman NI and Poh CL: Development of microRNAs as potential therapeutics against cancer. J Oncol. 2020:80297212020. View Article : Google Scholar : PubMed/NCBI
74	Wang V and Wu W: MicroRNA-based therapeutics for cancer. BioDrugs. 23:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
75	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
76	Shah V and Shah J: Recent trends in targeting miRNAs for cancer therapy. J Pharm Pharmacol. 72:1732–1749. 2020. View Article : Google Scholar : PubMed/NCBI
77	Lu PY, Xie F and Woodle MC: In vivo application of RNA interference: From functional genomics to therapeutics. Adv Genet. 54:117–142. 2005.PubMed/NCBI
78	Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W and Aebischer P: Lentiviral-mediated RNA interference. Hum Gene Ther. 13:2197–2201. 2002. View Article : Google Scholar : PubMed/NCBI
79	Tong AW: Small RNAs and non-small cell lung cancer. Curr Mol Med. 6:339–349. 2006. View Article : Google Scholar : PubMed/NCBI
80	Hanna J, Hossain GS and Kocerha J: The potential for microRNA therapeutics and clinical research. Front Genet. 10:4782019. View Article : Google Scholar : PubMed/NCBI
81	Si W, Shen J, Zheng H and Fan W: The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 11:252019. View Article : Google Scholar : PubMed/NCBI
82	Samji P, Rajendran MK, Warrier VP, Ganesh A and Devarajan K: Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective. Cell Signal. 78:1098582021. View Article : Google Scholar : PubMed/NCBI
83	Wang ZX, Lu BB, Wang H, Cheng ZX and Yin YM: MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 42:281–290. 2011. View Article : Google Scholar : PubMed/NCBI
84	Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H and Song E: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. Biol Chem. 286:19127–19137. 2011. View Article : Google Scholar : PubMed/NCBI
85	Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X, Huang Z, Zhu W, Shu Y and Liu P: miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 19:677–683. 2013. View Article : Google Scholar : PubMed/NCBI
86	Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, et al: miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 105:1750–1758. 2013. View Article : Google Scholar : PubMed/NCBI
87	Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S and Zhang Y: MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One. 9:e1155652014. View Article : Google Scholar : PubMed/NCBI
88	Feng YH and Tsao CJ: Emerging role of microRNA-21 in cancer. Biomed Rep. 5:395–402. 2016. View Article : Google Scholar : PubMed/NCBI
89	Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE and Altman RB: Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI
90	Tai W, Mahato R and Cheng K: The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
91	González-Alonso P, Zazo S, Martín-Aparicio E, Luque M, Chamizo C, Sanz-Álvarez M, Minguez P, Gómez-López G, Cristóbal I, Caramés C, et al: The hippo pathway transducers YAP1/TEAD induce acquired resistance to trastuzumab in HER2-positive breast cancer. Cancers (Basel). 12:11082020. View Article : Google Scholar : PubMed/NCBI
92	Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM and Yang PC: MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun. 4:18772013. View Article : Google Scholar : PubMed/NCBI
93	Mandati V, Del Maestro L, Dingli F, Lombard B, Loew D, Molinie N, Romero S, Bouvard D, Louvard D, Gautreau AM, et al: Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression. J Biol Chem. 294:12992–13005. 2019. View Article : Google Scholar : PubMed/NCBI
94	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
95	Gauthier A and Ho M: Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
96	Wu XZ, Xie GR and Chen D: Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 22:1178–1182. 2007. View Article : Google Scholar : PubMed/NCBI
97	Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park JH, Park WS, Shokat KM, Ha J and Kim SS: Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol. 54:328–339. 2011. View Article : Google Scholar : PubMed/NCBI
98	Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 99:1441–1454. 2007. View Article : Google Scholar : PubMed/NCBI